


Asymmetric Synthesis of Camptothecin Alkaloids: A Nine-Step Synthesis of (*S*)-Camptothecin.

Daniel L. Comins,* Hao Hong and Gao Jianhua

Department of Chemistry
 North Carolina State University, Raleigh, NC 27695-8204

Abstract: DE Ring camptothecin intermediate II was prepared enantioselectively from 2-chloro-6-hydroxypyridine in six steps and used in a nine-step synthesis of (*S*)-camptothecin.

(*S*)-Camptothecin (I) continues to be one of the most important lead compounds among the anticancer natural products.¹ We recently reported a 10 step, asymmetric synthesis of I.² The synthetic sequence involved coupling key intermediate II to bromoquinoline III followed by a final C-ring cyclization using a Heck reaction.




We are continuing to develop new routes to the DE ring intermediate II, and reported herein is a new preparation starting from 2-chloro-6-hydroxypyridine (1).


The hydroxyl group of 1 was protected on treatment with sodium hydride and chloromethyl ethyl ether in methylene chloride to give 2 (42%). The crude product contained approximately an equal amount of the *N*-alkylated product, which was easily separated by radial PLC (silica gel, 5% EtOAc/hexanes). Pyridine 2 was subjected to directed lithiation³ (*n*-BuLi, THF, -10 °C, 10 min) and trapping with *N*-formyl-*N,N,N'*-trimethylethylenediamine⁴ (3) (-23 °C, 30 min) to give an α -amino alkoxide in situ. Addition of *n*-BuLi (-23 °C, 4 h) effected α -amino alkoxide directed lithiation⁵ at C-4 to give the dianion 4. Addition of iodine and workup with NaBH₄/water provided a 41% yield of alcohol 5 (mp 43-44 °C) via a one-pot process. Formation of the 1,3-dioxane 6 (mp 142-144 °C) occurred on treatment of 5 with BF₃·OEt₂ in methylene chloride. Lithium-iodine exchange (THF, -100 °C, 1 min) and addition of α -ketobutyrate 7, prepared from α -ketobutyric acid (Aldrich) and (-)-*trans*-2-(α -cumyl)cyclohexanol⁶ ((-)-TCC), gave the crude product 8 with a dc of 88%.

Purification by radial PLC (silica gel, 10% EtOAc/hexanes) removed the minor diastereomer and provided a 63% yield of hydroxyester **8** as an oil $[[\alpha]_D^{23} - 1.55^\circ (c 1.1, \text{MeOH})]$. Hydrolysis of **8** with 10% HCl in methanol/water (reflux, 36 h) gave after concentration a crude solid, which was extracted twice with hot hexanes. The hexane extracts were concentrated to give recovered (-)-TCC in 97% yield. The remaining solid residue was recrystallized from EtOAc to provide a 75% yield of chloro DE rings **9** as white crystals, mp 216 - 218 °C (dec); $[\alpha]_D^{27} + 76.5 (c 1.3, \text{MeOH})$ [lit.² mp 219 - 220 °C; $[\alpha]_D^{23} + 58.5 (c 0.85, \text{MeOH})]$. Catalytic hydrogenation of **9** gave camptothecin intermediate **II** (95%), which was identical to material prepared by our previous route.²

Although the overall yield of **II** is less than obtained by our previous preparation, this synthesis has some advantages: (1) *t*-BuLi is not required; (2) the chloro DE rings **9** is prepared by a simple hydrolysis of its precursor **8**; and (3) the chiral auxiliary (-)-TCC can be easily recovered from the crude solid product by hexane extraction.



A modification of our previous synthesis² was used to convert DE rings II into (*S*)-camptothecin (I). We treated 2-bromoquinoline⁷ (10) with LDA and formaldehyde/THF to give alcohol 11.⁸ The Mitsunobu reaction^{9,10} was utilized to couple the DE rings II with 11. In this manner tetracyclic intermediate 12 was prepared in 84% yield. In our previous synthesis², 12 was converted to camptothecin in 59% yield using a Heck reaction.¹¹ For the purpose of exploring other methods for closing the C ring, we investigated a free-radical reaction. Treatment of 12 with tributyltin hydride (2 equiv) and AIBN in toluene gave a 55% yield of (*S*)-camptothecin (I), mp 272-275 °C dec; $[\alpha]_D^{23} + 44^\circ$ (c 0.32, CHCl₃/MeOH, 4:1) [lit.¹² mp 275-278 °C dec; lit.¹³ $[\alpha]_D + 42^\circ$ (c 0.51, CHCl₃/MeOH, 4:1)]. To our knowledge this is the first example of a free-radical arylation of a 2-pyridone. Our synthetic I was identical in every respect with authentic material.¹⁴ Work is underway to improve the overall yield of this synthesis and to develop other routes to camptothecin intermediate II and derivatives.¹⁵



Acknowledgement. We wish to express appreciation to Glaxo, Inc. for support of this work. NMR and mass spectra were obtained at NCSU instrumentation laboratories, which were established by grants from the North Carolina Biotechnology Center and the National Science Foundation (Grant CHE-8417529).

References and Notes

1. Reviews: Cia, J. C.; Hutchinson, C. R. *Chem. Heterocycl. Compd.* **1983**, *25*, 753. (b) Cia, J. C.; Hutchinson, C. R. *The Alkaloids: Chemistry and Pharmacology*; Brossi, A., Ed.; Academic Press: New York, 1983; Vol. 21, p. 101. (c) Hutchinson, C. R. *Tetrahedron* **1981**, *37*, 1047. (d) Schultz, A. G. *Chem. Rev.* **1973**, *73*, 385.
2. (a) Comins, D. L.; Baevsky, M. F.; Hong, H. *J. Am. Chem. Soc.* **1992**, *114*, 10971. (b) Comins, D. L.; Baevsky, M. F. U. S. Patent Nos. 5,162,632 (1992); 5,192,082 (1993); 5,254,690 (1993); 5,258,516 (1993); 5,262,579(1993).
3. (a) For an excellent review on ortho lithiation, see: Snieckus, V. *Chem. Rev.* **1990**, *90*, 879-933. (b) Comins, D. L.; LaMunyon, D. H. *Tetrahedron Lett.* **1988**, *29*, 773. (c) Marsais, F.; Le Nard, G.; Queguiner, G. *Synthesis*, **1982**, 235.
4. Einhorn, J.; Luche, J. L. *Tetrahedron Lett.* **1986**, *27*, 1791.
5. (a) Comins, D. L.; Killpack, M. O. *J. Org. Chem.* **1990**, *55*, 69. (b) For a review of α -amino alkoxide directed lithiations, see: Comins, D. L. *Synlett* **1992**, 615.
6. (a) Comins, D. L.; Salvador, J. M. *Tetrahedron Lett.* **1993**, *34*, 801. (b) Comins, D. L.; Salvador, J. M. *J. Org. Chem.* **1993**, *58*, 4656 and references cited therein.
7. Young, T. E.; Amstutz, E. D. *J. Am. Chem. Soc.* **1951**, *73*, 4773.
8. For the C-3 lithiation of 2-chloroquinoline with LDA, see: Marsais, F.; Godard, A.; Queguiner, G. *J. Heterocycl. Chem.* **1989**, *26*, 1589.
9. For reviews, see: (a) Mitsunobu, O. *Synthesis* **1981**, 1-28. (b) Hughes, D. L. *Org. React.* **1992**, *42*, 335-656.
10. For alkylation of 2-pyridones using the Mitsunobu reaction, see: Comins, D. L.; Jianhua, G. *Tetrahedron Lett.*, in press.
11. Grigg, R.; Sridharan, V.; Stevenson, P.; Sukirthalingam, S.; Worakun, T. *Tetrahedron*. **1990**, *46*, 4003.
12. Corey, E. J.; Crouse, D. N.; Anderson, J. E. *J. Org. Chem.* **1975**, *40*, 2140.
13. Ejima, A.; Terasawa, H.; Sugimori, M.; Tagawa, H. *Tetrahedron Lett.* **1989**, *30*, 2639.
14. A sample of natural camptothecin was kindly supplied by Glaxo, Inc., Research Triangle Park, NC.
15. For recent synthetic work on the camptothecin alkaloids, see: (a) Curran, D. P.; Liu, H. *J. Am. Chem. Soc.* **1992**, *114*, 5863. (b) Shen, W.; Coburn, C. A.; Bornmann, W. G.; Danishefsky, S. J. *J. Org. Chem.* **1993**, *58*, 611 and references cited therein.

(Received in USA 18 April 1994; accepted 27 May 1994)